Cargando…

Next generations of CAR-T cells - new therapeutic opportunities in hematology?

In recent years, the introduction of chimeric antigen receptor (CAR) T-cell therapies into clinics has been a breakthrough in treating relapsed or refractory malignancies in hematology and oncology. To date, Food and Drug Administration (FDA) has approved six CAR-T therapies for specific non-Hodgkin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomasik, Jaromir, Jasiński, Marcin, Basak, Grzegorz W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650233/
https://www.ncbi.nlm.nih.gov/pubmed/36389658
http://dx.doi.org/10.3389/fimmu.2022.1034707